证券代码：688053 证券简称：思科瑞 公告编号：2024-023 成都思科瑞微电子股份有限公司 2023 年年度股东大会决议公告 本公司董事会及除张亚先生外的董事保证公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2024 年 5 月 24 日 （二） 股东大会召开的地点：成都市龙泉驿区驿都大道中路 337 号恒鼎世纪酒 店 22 楼 5 号会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 7 | | --- | --- | | 普通股股东人数 | 7 | | 2、出席会议的股东所持有的表决权数量 | 65,037,557 | | 普通股股东所持有表决权数量 | 65,037,557 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的 | 65.6479 | | 比例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例 | 6 ...

广东省深圳市福田区中心四路 1-1 号 嘉里建设广场第三座第 28 层 2803-04 室 邮编：518048 电话：（86-755）2939-5288 传真：（86-755）2939-5289 junhesz@junhe.com 北京市君合（深圳）律师事务所 关于成都思科瑞微电子股份有限公司 2023 年年度股东大会的法律意见书 致：成都思科瑞微电子股份有限公司 北京市君合（深圳）律师事务所（以下简称"本所"）接受成都思科瑞微电 子股份有限公司（以下简称"贵公司"或"公司"）的委托，就贵公司 2023 年年 度股东大会（以下简称"本次股东大会"）召开的有关事宜，根据《中华人民共 和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》、中国证券监 督管理委员会颁布的《上市公司股东大会规则》（以下简称"《股东大会规则》"） 等中国现行法律、法规、规章、规范性文件（以下简称"中国法律、法规"，为 出具本法律意见书之目的，"中国"不包括香港特别行政区、澳门特别行政区和 台湾省）及现行《成都思科瑞微电子股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，出具本法律意见书。 本法律意见书仅就本次股东大 ...

成都思科瑞微电子股份有限公司 2023 年年度股东大会会议资料 证券代码：688053 证券简称：思科瑞 成都思科瑞微电子股份有限公司 2023 年年度股东大会 会议资料 2024 年 5 月 | | | | 2023 年年度股东大会会议须知 1 | | --- | | 2023 年年度股东大会会议议程 4 | | 2023 年年度股东大会会议议案 6 | | 议案一 6 | | 《关于 2023 年度董事会工作报告的议案》 6 | | 议案二 7 | | 《关于 2023 年度独立董事履职情况报告的议案》 7 | | 议案三 8 | | 《关于 2023 年度监事会工作报告的议案》 8 | | 议案四 9 | | 《关于 2023 年度财务决算报告的议案》 9 | | 议案五 10 | | 《关于 2023 年年度报告及其摘要的议案》 10 | | 议案六 11 | | 《关于 2023 年度利润分配方案的议案》 11 | | 议案七 13 | | 《关于续聘会计师事务所的议案》 13 | | 议案八 14 | | 《关于 2024 年度董事薪酬方案的议案》 14 | | 议案九 15 | | 《关于 20 ...

中国银河证券股份有限公司 关于成都思科瑞微电子股份有限公司 2023 年度持续督导跟踪报告 中国银河证券股份有限公司（以下简称"银河证券"或"保荐机构"）作为 成都思科瑞微电子股份有限公司（以下简称"思科瑞"或"公司"）首次公开发 行股票并在科创板上市项目的保荐机构，根据《证券发行上市保荐业务管理办法》 《上海证券交易所科创板股票上市规则》《上海证券交易所上市公司自律监管指 引第 11 号——持续督导》等相关规定，负责思科瑞上市后的持续督导工作，并 出具本持续督导跟踪报告。 | 序 | 工作内容 | 实施情况 | | --- | --- | --- | | 号 | | | | 1 | 建立健全并有效执行持续督导工作制度，并针对 | 保荐机构已建立健全并有效执行了持续督导 | | | 具体的持续督导工作制定相应的工作计划。 根据中国证监会相关规定，在持续督导工作开始 | 制度，并制定了相应的工作计划。 | | 2 | | 保荐机构已与思科瑞签订保荐协议，该协议 | | | 前，与上市公司签署持续督导协议，明确双方在 | 明确了双方在持续督导期间的权利和义务， | | | 持续督导期间的权利义务，并报上海证券交易 ...

截至 2024 年 4 月 30 日，公司通过上海证券交易所交易系统以集中竞价交易 成都思科瑞微电子股份有限公司 关于回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2023/8/25，由实际控制人、董事长张亚先生提议 | | --- | --- | | 回购方案实施期限 | 2023/8/23 ~2024/8/22 | | 预计回购金额 | 3,000 万元~5,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 92.9677 万股 | | 累计已回购股数占总股本比 | 0.93% | | 例 | | | 累计已回购金额 | 万元 4,048.07 | | 实际回购价格区间 | 元/股~59.90 元/股 23.29 | 一、 回购股份的基本情况 公司于 2023 年 8 月 23 日召开第二届董事会第二次会议，审议通过了《关 ...

证券代码：688053 证券简称：思科瑞 公告编号：2024-022 成都思科瑞微电子股份有限公司 关于召开 2023 年度暨 2024 年第一季度业绩说明会 的公告 本公司董事会及除张亚先生外的董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承 担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 05 月 09 日(星期四) 至 05 月 15 日(星期三)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 security@cd-screen.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答成都思科瑞微电子股份有限公司（以下简称"公司"）已分别于 2024 年 4 月 29 日和 2024 年 4 月 30 日发布了公司 2023 年度报告和公司 2024 年第一季 度报告，为便于广大投资者更全面深入地了解公司 2023 年度及 2024 年第一季 度经营成果、财务状况，公司计划于 2024 年 05 月 16 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥28,670,179.99, representing a decrease of 55.01% compared to the same period last year[4]. - The net profit attributable to shareholders was ¥4,571,726.52, down 80.47% year-on-year[4]. - The net profit after deducting non-recurring gains and losses was ¥3,357,116.13, a decline of 85.60% compared to the previous year[5]. - The basic and diluted earnings per share were both ¥0.05, reflecting a decrease of 78.26% year-on-year[5]. - Total operating revenue for Q1 2024 was CNY 28,670,179.99, a decrease of 55.1% compared to CNY 63,719,430.62 in Q1 2023[22]. - Net profit for Q1 2024 was CNY 3,276,392.33, a decline of 86.0% from CNY 23,413,414.12 in Q1 2023[23]. - Earnings per share for Q1 2024 was CNY 0.05, compared to CNY 0.23 in Q1 2023[23]. Cash Flow and Liquidity - The net cash flow from operating activities increased significantly by 473.04%, amounting to ¥23,596,244.96[5]. - The company's cash and cash equivalents decreased from RMB 308.30 million on December 31, 2023, to RMB 238.36 million as of March 31, 2024, representing a decline of approximately 22.67%[16]. - The ending cash and cash equivalents balance decreased to $238,364,031.05 from $608,619,985.53, a drop of 60.9% year-over-year[26]. - The company reported a cash inflow from other operating activities of $2,274,775.83, up from $655,295.64, representing a growth of 247.5%[25]. - The net cash flow from operating activities reached $23,596,244.96, significantly up from $4,117,741.59 in the same period last year, marking a growth of 471.5%[25]. - The net cash flow from investing activities was -$82,319,678.08, a decline from $442,920,394.48 in Q1 2023, indicating a significant shift in investment strategy[26]. - The net cash flow from financing activities was -$11,212,636.27, worsening from -$5,938,257.76 in Q1 2023, indicating increased financial strain[26]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,833,421,594.41, a decrease of 0.49% from the end of the previous year[5]. - Total assets as of Q1 2024 amounted to CNY 1,833,421,594.41, slightly down from CNY 1,842,516,345.64 in the previous quarter[18]. - Total liabilities for Q1 2024 were CNY 110,659,026.08, a decrease of 3.0% from CNY 115,023,655.78 in the previous quarter[18]. - The total current assets decreased from RMB 1.34 billion on December 31, 2023, to RMB 1.27 billion as of March 31, 2024, reflecting a decrease of about 5.37%[16]. Operational Challenges - The company faced a decline in revenue primarily due to a temporary adjustment in the downstream military industry, leading to delayed military orders[7]. - The increase in unit operating costs contributed to the decline in gross profit margin[7]. - The company invested in equipment and facility leasing to expand testing capacity, resulting in increased depreciation costs[8]. Shareholder and Management Changes - As of March 31, 2024, the company has repurchased a total of 824,481 shares, accounting for 0.82% of the total share capital, with a total expenditure of approximately RMB 37.99 million[14]. - The company has appointed Ma Weidong as the acting chairman and legal representative during the absence of the actual controller Zhang Ya, who is currently under detention[13]. - There are no changes in the top 10 shareholders or the top 10 unrestricted shareholders due to the transfer of shares for margin trading[13]. Future Outlook - The company has not disclosed any new product developments or technological advancements in the current report[12]. - The company has not reported any significant market expansion or acquisition strategies in the current quarter[12]. - The company plans to focus on new product development and market expansion strategies in the upcoming quarters, although specific details were not provided in the content[24].

成都思科瑞微电子股份有限公司 监事会议事规则 （2024 年 4 月修订） 第一章 总 则 第一条 为进一步保障成都思科瑞微电子股份有限公司（以下简称"公 司"）的监事会依法有效地履行职责，完善公司法人治理结构，根据《中华人民 共和国公司法》（以下简称"《公司法》"）、《成都思科瑞微电子股份有限公司章 程》（以下简称"《公司章程》"）及其他有关法律、行政法规、部门规章及规范性 文件的规定，制订成都思科瑞微电子股份有限公司监事会议事规则（以下简称"本 议事规则"）。 第二条 监事会是公司的常设监督机构，对股东大会负责，由股东大会 选举产生。监事会应当依法检查公司财务，监督董事、高级管理人员履职的合法 合规性，行使《公司章程》规定的其他职权，维护公司及股东的合法权益。 第三条 监事、监事会依据法律、行政法规、部门规章和《公司章程》 的规定行使职权，公司应当采取有效措施保障监事的知情权，公司董事会、总经 理、公司各部门及分支机构应当予以配合，并提供必要的保障，公司任何机构和 个人不得干预或干扰监事和监事会正常行使职权。 第四条 监事应当遵守法律、行政法规和《公司章程》，对公司负有忠实 义务和勤勉义务，不得利用职权收 ...

成都思科瑞微电子股份有限公司 内部控制审计报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 www.zhcpa.cn DK 明该审计报告是否由具有执业许可的会计师事务所出 所行业统一监管平台（http://acc.mof.gov.cn） 进行查 您可使用手机"扫一扫"或进入"注册会 报告编码:浙24K7M7U6F2 内部控制审计报告 中汇会审[2024]5586号 成都思科瑞微电子股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我 们审计了成都思科瑞微电子股份有限公司(以下简称成都思科瑞公司)2023年12月 31日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部 控制评价指引》的规定,建立健全和有效 ...

Financial Performance - The net profit attributable to ordinary shareholders for 2023 is RMB 43,097,713.78, with a distributable profit of RMB 106,778,476.52 as of December 31, 2023[7]. - The proposed cash dividend is RMB 3.10 per 10 shares, totaling RMB 30,711,800.13, which represents 71.26% of the net profit attributable to shareholders[8]. - The company reported a significant increase in revenue, reaching RMB 1.2 billion, representing a 25% year-over-year growth[30]. - The company's operating revenue for 2023 was CNY 195,003,070.81, a decrease of 19.69% compared to CNY 242,821,756.97 in 2022[31]. - Net profit attributable to shareholders decreased by 55.75% to CNY 43,097,713.78 from CNY 97,393,341.33 in the previous year[31]. - Basic and diluted earnings per share fell by 62.28% to CNY 0.43, primarily due to an increase in the weighted average number of shares outstanding[33]. - The gross profit margin for 2022 and 2023 was 68.16% and 52.75%, respectively, indicating a significant decline in profitability[113]. - The main business revenue from reliability testing decreased by 16.98% to CNY 185,068,952.03, while the corresponding costs increased by 26.41%[127]. Operational Highlights - User data showed an increase in active users by 15%, totaling 3 million active users by the end of the fiscal year[30]. - The company plans to increase its workforce by 20% to support growth initiatives and new product development[30]. - The company has established partnerships with three major industry players to enhance its supply chain efficiency[30]. - The company has successfully expanded its detection capacity from 201 items to 378 items, enhancing its ability to undertake detection and screening services[56]. - The company has established a business layout centered around Chengdu, Xi'an, and Wuxi, expanding its market coverage in Southwest, Northwest, and East China[54]. Research and Development - Research and development expenses accounted for 11.43% of operating revenue, an increase of 2.65 percentage points compared to the previous year[33]. - The company invested RMB 300 million in new technology development, focusing on AI and machine learning applications[30]. - The company has developed over 36,000 testing programs, including more than 33,000 self-developed programs, over 3,000 equipment matching programs, and around 380 externally purchased programs[69]. - The company has added 51 new intellectual property items during the reporting period, including 14 invention patents and 30 software copyrights, bringing the total to 288 intellectual property items[93]. - The company has enhanced its integrated circuit reliability testing capabilities, achieving a DDR3 testing speed of up to 2.4Gbps and a high-precision AD/DA detection resolution of 24bit[90]. Market Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[30]. - The company plans to implement a new marketing strategy aimed at increasing brand awareness, with a budget allocation of 50 million yuan[194]. - The company aims to establish a first-class reliability service platform in China by 2024, focusing on long-term development and optimizing management to enhance efficiency and quality[163]. - The company will focus on talent development, particularly in technical R&D and marketing, to strengthen its core competitiveness and build a high-performance team[169]. Risk Factors - The company has described potential risks in the "Management Discussion and Analysis" section, urging investors to pay attention to investment risks[5]. - The company faces risks related to talent retention, as the industry is experiencing intense competition for skilled professionals[112]. - There is a risk of major quality incidents affecting the company's credibility and brand, which could impact business operations[111]. - The company’s reliance on military electronic component reliability testing may be impacted by changes in national defense policies and standards[117]. Governance and Compliance - The board of directors consists of 7 members, including 3 independent directors, complying with legal requirements[173]. - The company has established four specialized committees under the board: strategy, nomination, compensation and assessment, and audit, ensuring effective decision-making[173]. - The company has consistently disclosed information accurately and timely, including the 2023 semi-annual and quarterly reports[175]. - The company has approved a restricted stock incentive plan for 2023, enhancing employee motivation and retention[179].